Results 31 to 40 of about 1,731,031 (302)

Putting the quality into quality-adjusted life years [PDF]

open access: yesJournal of Public Health, 2003
Over recent decades, a great deal of effort has been devoted towards developing instruments that can be used to elicit health state values. All of these instruments are conceptually very different from one another and all suffer from serious inherent biases.
openaire   +2 more sources

Quality-Adjusted Life-Years without Constant Proportionality [PDF]

open access: yesValue in Health, 2018
A quality-adjusted life-year is a common unit of measurement in health valuation. Under its constant proportionality assumption, the value of a quality-adjusted life span is defined as the product of preference weight and life span.To empirically identify an alternative functional relationship between life span and value by relaxing the constant ...
Craig, Benjamin M.   +3 more
openaire   +3 more sources

Fundamental Measurement: The Need Fulfilment Quality of Life (N-QOL) Measure

open access: yesINNOVATIONS in Pharmacy, 2021
The quality adjusted life year (QALY) has serious problems related to its failure to adhere to measurement theory. If a QALY is to be meaningful, the utility score that translates time spent to an equivalent time spent in so-called perfect health must ...
Paul C. Langley, Stephen P. McKenna
doaj   +1 more source

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis [PDF]

open access: yes, 2003
OBJECTIVE: To evaluate the cost effectiveness of four disease modifying treatments (interferon betas and glatiramer acetate) for relapsing remitting and secondary progressive multiple sclerosis in the United Kingdom. DESIGN: Modelling cost effectiveness.
Abrams, K.   +6 more
core   +2 more sources

Survival Outcomes and Complications Among Canadian Children With Retinoblastoma: A Population‐Based Report From CYP‐C

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Retinoblastoma (RB) is the most common pediatric ocular cancer, yet population‐based data on survival and risk factors remain limited. This study aimed to describe survival in a large national RB cohort and identify predictors of death and complications.
Samuel Sassine   +14 more
wiley   +1 more source

Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács   +8 more
wiley   +1 more source

The Proposal and Application of Quality-adjusted Life Years

open access: yesYixue yu zhexue
Quality-adjusted life years (QALYs) is a quantitative health measure that integrates both life expectancy and quality, proposed in the 1970s as an effective tool for aiding the rational allocation of healthcare resources while balancing efficiency and ...
Yixuan LI
doaj   +1 more source

Measuring the impact of alcohol-related disorders on quality of life through general population preferences

open access: yesGaceta Sanitaria, 2017
Objective: To estimate the intangible effects of alcohol misuse on the drinker's quality of life, based on general population preferences Methods: The most important effects (dimensions) were identified by means of two focus groups conducted with ...
Eva Rodríguez-Míguez   +1 more
doaj   +1 more source

Income-related inequality in life-years and quality-adjusted life-years [PDF]

open access: yesJournal of Health Economics, 2000
We estimate the income-related inequality in Sweden with respect to life-years and quality-adjusted life-years (QALYs). We use a large data set from Sweden with over 40,000 individuals followed up for 10-16 years, to estimate the survival and quality-adjusted survival in different income groups.
Gerdtham, Ulf-G., Johannesson, Magnus
openaire   +3 more sources

Sirolimus for Extracranial Arteriovenous Malformations: A Scoping Review of the Evidence in Syndromic and Non‐Syndromic Cases

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Arteriovenous malformations (AVMs) are rare, high‐flow, vascular anomalies that can occur either sporadically or as part of a genetic syndrome. AVMs can progress with serious morbidity and even mortality if left unchecked. Sirolimus is an mTOR inhibitor that is effective in low‐flow vascular malformations; however, its role in AVMs is unclear.
Will Swansson   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy